Your browser doesn't support javascript.
loading
Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials.
Willeit, Peter; Ridker, Paul M; Nestel, Paul J; Simes, John; Tonkin, Andrew M; Pedersen, Terje R; Schwartz, Gregory G; Olsson, Anders G; Colhoun, Helen M; Kronenberg, Florian; Drechsler, Christiane; Wanner, Christoph; Mora, Samia; Lesogor, Anastasia; Tsimikas, Sotirios.
Afiliação
  • Willeit P; Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria; Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK. Electronic address: peter.willeit@i-med.ac.at.
  • Ridker PM; Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Nestel PJ; Baker Heart and Diabetes Institute, Melbourne, Vic, Australia.
  • Simes J; NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia.
  • Tonkin AM; Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Vic, Australia.
  • Pedersen TR; Oslo University Hospital, Ullevål, and Medical Faculty, University of Oslo, Oslo, Norway.
  • Schwartz GG; Division of Cardiology, VA Medical Center and University of Colorado School of Medicine, Denver, CO, USA.
  • Olsson AG; Department of Medicine and Care, Faculty of Health Sciences, University of Linköping, Linköping, Sweden.
  • Colhoun HM; MRC Human Genetics Unit, Centre for Genomic and Experimental Medicine, MRC Institute of Genetics & Molecular Medicine, Edinburgh, UK.
  • Kronenberg F; Division of Genetic Epidemiology, Department of Medical Genetics, Molecular and Clinical Pharmacology, Medical University of Innsbruck, Innsbruck, Austria.
  • Drechsler C; Division of Nephrology, Department of Internal Medicine 1 and Comprehensive Heart Failure Centre, University Hospital of Würzburg, Würzburg, Germany.
  • Wanner C; Division of Nephrology, Department of Internal Medicine 1 and Comprehensive Heart Failure Centre, University Hospital of Würzburg, Würzburg, Germany.
  • Mora S; Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Lesogor A; Novartis Pharma AG, Basel, Switzerland.
  • Tsimikas S; Vascular Medicine Program, Sulpizio Cardiovascular Center, Division of Cardiology, Department of Medicine, University of California San Diego, La Jolla, CA, USA. Electronic address: stsimikas@ucsd.edu.
Lancet ; 392(10155): 1311-1320, 2018 10 13.
Article em En | MEDLINE | ID: mdl-30293769
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Cardiovasculares / Lipoproteína(a) / Inibidores de Hidroximetilglutaril-CoA Redutases / Hipercolesterolemia Tipo de estudo: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Ano de publicação: 2018 Tipo de documento: Article
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Cardiovasculares / Lipoproteína(a) / Inibidores de Hidroximetilglutaril-CoA Redutases / Hipercolesterolemia Tipo de estudo: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Ano de publicação: 2018 Tipo de documento: Article